nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—Loperamide—Tamoxifen—pancreatic cancer	0.236	1	CrCrCtD
Haloperidol—EBP—Tamoxifen—pancreatic cancer	0.118	0.2	CbGbCtD
Haloperidol—CBR1—Doxorubicin—pancreatic cancer	0.0722	0.122	CbGbCtD
Haloperidol—SIGMAR1—Tamoxifen—pancreatic cancer	0.0508	0.0861	CbGbCtD
Haloperidol—UGT1A9—Irinotecan—pancreatic cancer	0.0333	0.0565	CbGbCtD
Haloperidol—CYP1A1—Dacarbazine—pancreatic cancer	0.0226	0.0384	CbGbCtD
Haloperidol—CYP1A1—Tamoxifen—pancreatic cancer	0.018	0.0305	CbGbCtD
Haloperidol—KCNH2—Sunitinib—pancreatic cancer	0.0158	0.0268	CbGbCtD
Haloperidol—CYP1A1—Erlotinib—pancreatic cancer	0.0153	0.026	CbGbCtD
Haloperidol—CYP3A7—Tamoxifen—pancreatic cancer	0.0144	0.0244	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0144	0.0244	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0111	0.0188	CbGbCtD
Haloperidol—CYP3A7—Irinotecan—pancreatic cancer	0.0111	0.0188	CbGbCtD
Haloperidol—CYP3A5—Tamoxifen—pancreatic cancer	0.0108	0.0183	CbGbCtD
Haloperidol—CYP1A2—Dacarbazine—pancreatic cancer	0.0101	0.0171	CbGbCtD
Haloperidol—CYP3A5—Erlotinib—pancreatic cancer	0.0092	0.0156	CbGbCtD
Haloperidol—CYP2C19—Tamoxifen—pancreatic cancer	0.00872	0.0148	CbGbCtD
Haloperidol—CYP3A5—Irinotecan—pancreatic cancer	0.0083	0.0141	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.00811	0.0137	CbGbCtD
Haloperidol—CYP3A7—Docetaxel—pancreatic cancer	0.00811	0.0137	CbGbCtD
Haloperidol—CYP3A7—Sunitinib—pancreatic cancer	0.00808	0.0137	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.00808	0.0137	CbGbCtD
Haloperidol—CYP1A2—Tamoxifen—pancreatic cancer	0.00805	0.0136	CbGbCtD
Haloperidol—CYP2C9—Tamoxifen—pancreatic cancer	0.00725	0.0123	CbGbCtD
Haloperidol—ABCB1—Tamoxifen—pancreatic cancer	0.00704	0.0119	CbGbCtD
Haloperidol—CYP1A2—Erlotinib—pancreatic cancer	0.00684	0.0116	CbGbCtD
Haloperidol—CYP2D6—Tamoxifen—pancreatic cancer	0.00663	0.0112	CbGbCtD
Haloperidol—CYP3A5—Docetaxel—pancreatic cancer	0.00609	0.0103	CbGbCtD
Haloperidol—ABCB1—Gemcitabine—pancreatic cancer	0.00606	0.0103	CbGbCtD
Haloperidol—CYP3A5—Sunitinib—pancreatic cancer	0.00606	0.0103	CbGbCtD
Haloperidol—ABCB1—Erlotinib—pancreatic cancer	0.00598	0.0101	CbGbCtD
Haloperidol—CYP1A2—Fluorouracil—pancreatic cancer	0.00593	0.0101	CbGbCtD
Haloperidol—CYP2D6—Erlotinib—pancreatic cancer	0.00564	0.00955	CbGbCtD
Haloperidol—ABCB1—Irinotecan—pancreatic cancer	0.0054	0.00916	CbGbCtD
Haloperidol—CYP2C9—Fluorouracil—pancreatic cancer	0.00534	0.00906	CbGbCtD
Haloperidol—CYP3A4—Tamoxifen—pancreatic cancer	0.00422	0.00715	CbGbCtD
Haloperidol—ABCB1—Docetaxel—pancreatic cancer	0.00396	0.00671	CbGbCtD
Haloperidol—ABCB1—Sunitinib—pancreatic cancer	0.00394	0.00668	CbGbCtD
Haloperidol—CYP3A4—Erlotinib—pancreatic cancer	0.00359	0.00608	CbGbCtD
Haloperidol—CYP3A4—Irinotecan—pancreatic cancer	0.00324	0.00549	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—pancreatic cancer	0.00295	0.005	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—pancreatic cancer	0.00278	0.00471	CbGbCtD
Haloperidol—CYP3A4—Docetaxel—pancreatic cancer	0.00237	0.00402	CbGbCtD
Haloperidol—CYP3A4—Sunitinib—pancreatic cancer	0.00236	0.004	CbGbCtD
Haloperidol—CYP3A4—Doxorubicin—pancreatic cancer	0.00177	0.003	CbGbCtD
Haloperidol—CBR1—Azacitidine—Gemcitabine—pancreatic cancer	0.00093	0.595	CbGdCrCtD
Haloperidol—HTR2A—enteric nervous system—pancreatic cancer	0.000779	0.263	CbGeAlD
Haloperidol—EBP—Azacitidine—Gemcitabine—pancreatic cancer	0.000633	0.405	CbGdCrCtD
Haloperidol—CBR1—islet of Langerhans—pancreatic cancer	0.000236	0.0796	CbGeAlD
Haloperidol—H1F0—islet of Langerhans—pancreatic cancer	0.000194	0.0652	CbGeAlD
Haloperidol—UGT1A9—digestive system—pancreatic cancer	0.000188	0.0635	CbGeAlD
Haloperidol—CBR1—digestive system—pancreatic cancer	0.000142	0.0478	CbGeAlD
Haloperidol—SIGMAR1—islet of Langerhans—pancreatic cancer	0.00014	0.0471	CbGeAlD
Haloperidol—Cardiac disorder—Docetaxel—pancreatic cancer	0.000139	0.00141	CcSEcCtD
Haloperidol—Cardiac arrest—Epirubicin—pancreatic cancer	0.000139	0.00141	CcSEcCtD
Haloperidol—Vomiting—Tamoxifen—pancreatic cancer	0.000139	0.00141	CcSEcCtD
Haloperidol—Hypoglycaemia—Doxorubicin—pancreatic cancer	0.000139	0.00141	CcSEcCtD
Haloperidol—Lethargy—Doxorubicin—pancreatic cancer	0.000138	0.0014	CcSEcCtD
Haloperidol—Hypotension—Fluorouracil—pancreatic cancer	0.000138	0.0014	CcSEcCtD
Haloperidol—Hypersensitivity—Sunitinib—pancreatic cancer	0.000138	0.0014	CcSEcCtD
Haloperidol—Rash—Tamoxifen—pancreatic cancer	0.000138	0.0014	CcSEcCtD
Haloperidol—Dermatitis—Tamoxifen—pancreatic cancer	0.000138	0.0014	CcSEcCtD
Haloperidol—Vomiting—Erlotinib—pancreatic cancer	0.000138	0.00139	CcSEcCtD
Haloperidol—Dyspnoea—Irinotecan—pancreatic cancer	0.000138	0.00139	CcSEcCtD
Haloperidol—Somnolence—Irinotecan—pancreatic cancer	0.000137	0.00139	CcSEcCtD
Haloperidol—Headache—Tamoxifen—pancreatic cancer	0.000137	0.00139	CcSEcCtD
Haloperidol—Rash—Erlotinib—pancreatic cancer	0.000137	0.00138	CcSEcCtD
Haloperidol—Dermatitis—Erlotinib—pancreatic cancer	0.000136	0.00138	CcSEcCtD
Haloperidol—Angiopathy—Docetaxel—pancreatic cancer	0.000136	0.00138	CcSEcCtD
Haloperidol—Hyponatraemia—Doxorubicin—pancreatic cancer	0.000136	0.00138	CcSEcCtD
Haloperidol—Insomnia—Gemcitabine—pancreatic cancer	0.000136	0.00138	CcSEcCtD
Haloperidol—H1F0—pancreas—pancreatic cancer	0.000136	0.0459	CbGeAlD
Haloperidol—Dyspepsia—Irinotecan—pancreatic cancer	0.000136	0.00138	CcSEcCtD
Haloperidol—Immune system disorder—Docetaxel—pancreatic cancer	0.000136	0.00137	CcSEcCtD
Haloperidol—Headache—Erlotinib—pancreatic cancer	0.000136	0.00137	CcSEcCtD
Haloperidol—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000135	0.00137	CcSEcCtD
Haloperidol—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000135	0.00137	CcSEcCtD
Haloperidol—Decreased appetite—Irinotecan—pancreatic cancer	0.000134	0.00136	CcSEcCtD
Haloperidol—Dyspnoea—Gemcitabine—pancreatic cancer	0.000134	0.00136	CcSEcCtD
Haloperidol—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000134	0.00135	CcSEcCtD
Haloperidol—Insomnia—Fluorouracil—pancreatic cancer	0.000134	0.00135	CcSEcCtD
Haloperidol—Somnolence—Gemcitabine—pancreatic cancer	0.000134	0.00135	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000133	0.00135	CcSEcCtD
Haloperidol—Alopecia—Docetaxel—pancreatic cancer	0.000133	0.00134	CcSEcCtD
Haloperidol—Pruritus—Sunitinib—pancreatic cancer	0.000133	0.00134	CcSEcCtD
Haloperidol—Breast disorder—Epirubicin—pancreatic cancer	0.000132	0.00134	CcSEcCtD
Haloperidol—Constipation—Irinotecan—pancreatic cancer	0.000132	0.00134	CcSEcCtD
Haloperidol—Dyspnoea—Fluorouracil—pancreatic cancer	0.000132	0.00134	CcSEcCtD
Haloperidol—Mental disorder—Docetaxel—pancreatic cancer	0.000132	0.00133	CcSEcCtD
Haloperidol—Somnolence—Fluorouracil—pancreatic cancer	0.000131	0.00133	CcSEcCtD
Haloperidol—Face oedema—Doxorubicin—pancreatic cancer	0.000131	0.00133	CcSEcCtD
Haloperidol—Malnutrition—Docetaxel—pancreatic cancer	0.000131	0.00132	CcSEcCtD
Haloperidol—Decreased appetite—Gemcitabine—pancreatic cancer	0.000131	0.00132	CcSEcCtD
Haloperidol—Dyspepsia—Fluorouracil—pancreatic cancer	0.00013	0.00132	CcSEcCtD
Haloperidol—Nausea—Tamoxifen—pancreatic cancer	0.00013	0.00132	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00013	0.00131	CcSEcCtD
Haloperidol—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000129	0.00131	CcSEcCtD
Haloperidol—Constipation—Gemcitabine—pancreatic cancer	0.000129	0.0013	CcSEcCtD
Haloperidol—Nausea—Erlotinib—pancreatic cancer	0.000129	0.0013	CcSEcCtD
Haloperidol—Decreased appetite—Fluorouracil—pancreatic cancer	0.000129	0.0013	CcSEcCtD
Haloperidol—Diarrhoea—Sunitinib—pancreatic cancer	0.000128	0.0013	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000128	0.00129	CcSEcCtD
Haloperidol—Feeling abnormal—Irinotecan—pancreatic cancer	0.000127	0.00129	CcSEcCtD
Haloperidol—Dysphagia—Epirubicin—pancreatic cancer	0.000127	0.00128	CcSEcCtD
Haloperidol—Muscle spasms—Docetaxel—pancreatic cancer	0.000126	0.00127	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000125	0.00127	CcSEcCtD
Haloperidol—Dizziness—Sunitinib—pancreatic cancer	0.000124	0.00126	CcSEcCtD
Haloperidol—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000124	0.00126	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000124	0.00125	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—pancreatic cancer	0.000123	0.00124	CcSEcCtD
Haloperidol—Body temperature increased—Irinotecan—pancreatic cancer	0.000122	0.00124	CcSEcCtD
Haloperidol—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000122	0.00123	CcSEcCtD
Haloperidol—Anaemia—Docetaxel—pancreatic cancer	0.000121	0.00122	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—pancreatic cancer	0.00012	0.00122	CcSEcCtD
Haloperidol—Vomiting—Sunitinib—pancreatic cancer	0.000119	0.00121	CcSEcCtD
Haloperidol—Body temperature increased—Gemcitabine—pancreatic cancer	0.000119	0.0012	CcSEcCtD
Haloperidol—Neutropenia—Epirubicin—pancreatic cancer	0.000118	0.0012	CcSEcCtD
Haloperidol—Rash—Sunitinib—pancreatic cancer	0.000118	0.0012	CcSEcCtD
Haloperidol—Dermatitis—Sunitinib—pancreatic cancer	0.000118	0.0012	CcSEcCtD
Haloperidol—Urticaria—Fluorouracil—pancreatic cancer	0.000118	0.00119	CcSEcCtD
Haloperidol—Headache—Sunitinib—pancreatic cancer	0.000117	0.00119	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—pancreatic cancer	0.000117	0.00119	CcSEcCtD
Haloperidol—Leukopenia—Docetaxel—pancreatic cancer	0.000117	0.00119	CcSEcCtD
Haloperidol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000117	0.00118	CcSEcCtD
Haloperidol—H1F0—digestive system—pancreatic cancer	0.000116	0.0392	CbGeAlD
Haloperidol—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000116	0.00117	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—pancreatic cancer	0.000115	0.00117	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—pancreatic cancer	0.000115	0.00116	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000114	0.00116	CcSEcCtD
Haloperidol—Hypersensitivity—Irinotecan—pancreatic cancer	0.000114	0.00115	CcSEcCtD
Haloperidol—Convulsion—Docetaxel—pancreatic cancer	0.000113	0.00115	CcSEcCtD
Haloperidol—Hypertension—Docetaxel—pancreatic cancer	0.000113	0.00114	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—pancreatic cancer	0.000113	0.00114	CcSEcCtD
Haloperidol—Nausea—Sunitinib—pancreatic cancer	0.000111	0.00113	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—pancreatic cancer	0.000111	0.00113	CcSEcCtD
Haloperidol—KCNH2—islet of Langerhans—pancreatic cancer	0.000111	0.0375	CbGeAlD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000111	0.00112	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—pancreatic cancer	0.00011	0.00111	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—pancreatic cancer	0.00011	0.00111	CcSEcCtD
Haloperidol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000109	0.0011	CcSEcCtD
Haloperidol—Dry mouth—Docetaxel—pancreatic cancer	0.000109	0.0011	CcSEcCtD
Haloperidol—Confusional state—Docetaxel—pancreatic cancer	0.000108	0.00109	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000107	0.00108	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000107	0.00108	CcSEcCtD
Haloperidol—Oedema—Docetaxel—pancreatic cancer	0.000107	0.00108	CcSEcCtD
Haloperidol—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000107	0.00108	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—pancreatic cancer	0.000107	0.00108	CcSEcCtD
Haloperidol—Pruritus—Gemcitabine—pancreatic cancer	0.000106	0.00108	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—pancreatic cancer	0.000106	0.00107	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000106	0.00107	CcSEcCtD
Haloperidol—Diarrhoea—Irinotecan—pancreatic cancer	0.000106	0.00107	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—pancreatic cancer	0.000105	0.00107	CcSEcCtD
Haloperidol—Nervous system disorder—Docetaxel—pancreatic cancer	0.000105	0.00106	CcSEcCtD
Haloperidol—Pruritus—Fluorouracil—pancreatic cancer	0.000105	0.00106	CcSEcCtD
Haloperidol—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000105	0.00106	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—pancreatic cancer	0.000104	0.00106	CcSEcCtD
Haloperidol—Tachycardia—Docetaxel—pancreatic cancer	0.000104	0.00105	CcSEcCtD
Haloperidol—Skin disorder—Docetaxel—pancreatic cancer	0.000104	0.00105	CcSEcCtD
Haloperidol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000103	0.00104	CcSEcCtD
Haloperidol—Dizziness—Irinotecan—pancreatic cancer	0.000102	0.00103	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—pancreatic cancer	0.000102	0.00103	CcSEcCtD
Haloperidol—Anorexia—Docetaxel—pancreatic cancer	0.000102	0.00103	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—pancreatic cancer	0.000101	0.00103	CcSEcCtD
Haloperidol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000101	0.00102	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—pancreatic cancer	0.0001	0.00101	CcSEcCtD
Haloperidol—Hypotension—Docetaxel—pancreatic cancer	9.98e-05	0.00101	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—pancreatic cancer	9.96e-05	0.00101	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—pancreatic cancer	9.94e-05	0.00101	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—pancreatic cancer	9.88e-05	0.001	CcSEcCtD
Haloperidol—SIGMAR1—pancreas—pancreatic cancer	9.83e-05	0.0331	CbGeAlD
Haloperidol—Vomiting—Irinotecan—pancreatic cancer	9.82e-05	0.000994	CcSEcCtD
Haloperidol—Dizziness—Fluorouracil—pancreatic cancer	9.78e-05	0.00099	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—pancreatic cancer	9.77e-05	0.000989	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—pancreatic cancer	9.75e-05	0.000987	CcSEcCtD
Haloperidol—Rash—Irinotecan—pancreatic cancer	9.74e-05	0.000986	CcSEcCtD
Haloperidol—Dermatitis—Irinotecan—pancreatic cancer	9.73e-05	0.000985	CcSEcCtD
Haloperidol—Headache—Irinotecan—pancreatic cancer	9.67e-05	0.00098	CcSEcCtD
Haloperidol—Insomnia—Docetaxel—pancreatic cancer	9.66e-05	0.000978	CcSEcCtD
Haloperidol—Vomiting—Gemcitabine—pancreatic cancer	9.56e-05	0.000968	CcSEcCtD
Haloperidol—Dyspnoea—Docetaxel—pancreatic cancer	9.52e-05	0.000964	CcSEcCtD
Haloperidol—Somnolence—Docetaxel—pancreatic cancer	9.49e-05	0.000961	CcSEcCtD
Haloperidol—Rash—Gemcitabine—pancreatic cancer	9.49e-05	0.00096	CcSEcCtD
Haloperidol—Dermatitis—Gemcitabine—pancreatic cancer	9.48e-05	0.000959	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—pancreatic cancer	9.47e-05	0.000959	CcSEcCtD
Haloperidol—Headache—Gemcitabine—pancreatic cancer	9.42e-05	0.000954	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—pancreatic cancer	9.41e-05	0.000952	CcSEcCtD
Haloperidol—Vomiting—Fluorouracil—pancreatic cancer	9.4e-05	0.000952	CcSEcCtD
Haloperidol—Dyspepsia—Docetaxel—pancreatic cancer	9.4e-05	0.000951	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—pancreatic cancer	9.38e-05	0.00095	CcSEcCtD
Haloperidol—Rash—Fluorouracil—pancreatic cancer	9.33e-05	0.000944	CcSEcCtD
Haloperidol—Dermatitis—Fluorouracil—pancreatic cancer	9.32e-05	0.000943	CcSEcCtD
Haloperidol—Decreased appetite—Docetaxel—pancreatic cancer	9.28e-05	0.00094	CcSEcCtD
Haloperidol—Headache—Fluorouracil—pancreatic cancer	9.27e-05	0.000938	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—pancreatic cancer	9.26e-05	0.000938	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	9.22e-05	0.000933	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—pancreatic cancer	9.22e-05	0.000933	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—pancreatic cancer	9.2e-05	0.000931	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—pancreatic cancer	9.19e-05	0.000931	CcSEcCtD
Haloperidol—CYP3A5—islet of Langerhans—pancreatic cancer	9.19e-05	0.031	CbGeAlD
Haloperidol—Nausea—Irinotecan—pancreatic cancer	9.17e-05	0.000929	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—pancreatic cancer	9.15e-05	0.000927	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—pancreatic cancer	9.13e-05	0.000925	CcSEcCtD
Haloperidol—Constipation—Docetaxel—pancreatic cancer	9.13e-05	0.000924	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—pancreatic cancer	9.04e-05	0.000915	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—pancreatic cancer	8.96e-05	0.000907	CcSEcCtD
Haloperidol—Nausea—Gemcitabine—pancreatic cancer	8.94e-05	0.000905	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—pancreatic cancer	8.88e-05	0.000899	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—pancreatic cancer	8.82e-05	0.000893	CcSEcCtD
Haloperidol—Feeling abnormal—Docetaxel—pancreatic cancer	8.8e-05	0.000891	CcSEcCtD
Haloperidol—Nausea—Fluorouracil—pancreatic cancer	8.79e-05	0.00089	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—pancreatic cancer	8.76e-05	0.000887	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—pancreatic cancer	8.7e-05	0.000881	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—pancreatic cancer	8.51e-05	0.000861	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—pancreatic cancer	8.48e-05	0.000859	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—pancreatic cancer	8.47e-05	0.000858	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—pancreatic cancer	8.45e-05	0.000856	CcSEcCtD
Haloperidol—Body temperature increased—Docetaxel—pancreatic cancer	8.44e-05	0.000854	CcSEcCtD
Haloperidol—HTR2B—digestive system—pancreatic cancer	8.37e-05	0.0282	CbGeAlD
Haloperidol—Vision blurred—Epirubicin—pancreatic cancer	8.32e-05	0.000842	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—pancreatic cancer	8.29e-05	0.000839	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—pancreatic cancer	8.22e-05	0.000832	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—pancreatic cancer	8.16e-05	0.000827	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—pancreatic cancer	8.15e-05	0.000826	CcSEcCtD
Haloperidol—Agitation—Epirubicin—pancreatic cancer	8.11e-05	0.000821	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—pancreatic cancer	7.93e-05	0.000803	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—pancreatic cancer	7.9e-05	0.0008	CcSEcCtD
Haloperidol—Hypersensitivity—Docetaxel—pancreatic cancer	7.87e-05	0.000796	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—pancreatic cancer	7.85e-05	0.000795	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—pancreatic cancer	7.69e-05	0.000779	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—pancreatic cancer	7.64e-05	0.000774	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—pancreatic cancer	7.62e-05	0.000771	CcSEcCtD
Haloperidol—Pruritus—Docetaxel—pancreatic cancer	7.55e-05	0.000765	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—pancreatic cancer	7.55e-05	0.000764	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—pancreatic cancer	7.5e-05	0.00076	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—pancreatic cancer	7.49e-05	0.000758	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	7.46e-05	0.000755	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—pancreatic cancer	7.35e-05	0.000744	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—pancreatic cancer	7.33e-05	0.000743	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—pancreatic cancer	7.31e-05	0.00074	CcSEcCtD
Haloperidol—Diarrhoea—Docetaxel—pancreatic cancer	7.3e-05	0.00074	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—pancreatic cancer	7.26e-05	0.000735	CcSEcCtD
Haloperidol—Oedema—Epirubicin—pancreatic cancer	7.2e-05	0.000729	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—pancreatic cancer	7.2e-05	0.000729	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—pancreatic cancer	7.07e-05	0.000716	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—pancreatic cancer	7.06e-05	0.000715	CcSEcCtD
Haloperidol—Dizziness—Docetaxel—pancreatic cancer	7.06e-05	0.000715	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—pancreatic cancer	7.05e-05	0.000714	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—pancreatic cancer	7.05e-05	0.000714	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—pancreatic cancer	7.03e-05	0.000712	CcSEcCtD
Haloperidol—CYP2C19—digestive system—pancreatic cancer	7e-05	0.0236	CbGeAlD
Haloperidol—Skin disorder—Epirubicin—pancreatic cancer	6.99e-05	0.000708	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—pancreatic cancer	6.96e-05	0.000705	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—pancreatic cancer	6.93e-05	0.000701	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	6.9e-05	0.000699	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—pancreatic cancer	6.86e-05	0.000695	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—pancreatic cancer	6.8e-05	0.000688	CcSEcCtD
Haloperidol—Vomiting—Docetaxel—pancreatic cancer	6.79e-05	0.000687	CcSEcCtD
Haloperidol—Rash—Docetaxel—pancreatic cancer	6.73e-05	0.000682	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—pancreatic cancer	6.73e-05	0.000681	CcSEcCtD
Haloperidol—Dermatitis—Docetaxel—pancreatic cancer	6.73e-05	0.000681	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—pancreatic cancer	6.72e-05	0.00068	CcSEcCtD
Haloperidol—Headache—Docetaxel—pancreatic cancer	6.69e-05	0.000677	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—pancreatic cancer	6.66e-05	0.000675	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—pancreatic cancer	6.66e-05	0.000675	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—pancreatic cancer	6.53e-05	0.000662	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—pancreatic cancer	6.52e-05	0.00066	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—pancreatic cancer	6.51e-05	0.000659	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—pancreatic cancer	6.5e-05	0.000658	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—pancreatic cancer	6.47e-05	0.000655	CcSEcCtD
Haloperidol—CYP3A5—pancreas—pancreatic cancer	6.46e-05	0.0218	CbGeAlD
Haloperidol—Hyperhidrosis—Doxorubicin—pancreatic cancer	6.44e-05	0.000652	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—pancreatic cancer	6.42e-05	0.00065	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—pancreatic cancer	6.4e-05	0.000648	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—pancreatic cancer	6.35e-05	0.000643	CcSEcCtD
Haloperidol—Nausea—Docetaxel—pancreatic cancer	6.34e-05	0.000642	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—pancreatic cancer	6.34e-05	0.000642	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—pancreatic cancer	6.26e-05	0.000634	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—pancreatic cancer	6.23e-05	0.00063	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	6.22e-05	0.000629	CcSEcCtD
Haloperidol—Constipation—Epirubicin—pancreatic cancer	6.16e-05	0.000623	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—pancreatic cancer	6.03e-05	0.00061	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—pancreatic cancer	5.94e-05	0.000601	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—pancreatic cancer	5.93e-05	0.000601	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—pancreatic cancer	5.92e-05	0.0006	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—pancreatic cancer	5.86e-05	0.000594	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—pancreatic cancer	5.79e-05	0.000586	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	5.75e-05	0.000582	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—pancreatic cancer	5.72e-05	0.000579	CcSEcCtD
Haloperidol—CYP1A2—digestive system—pancreatic cancer	5.72e-05	0.0193	CbGeAlD
Haloperidol—Constipation—Doxorubicin—pancreatic cancer	5.7e-05	0.000577	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—pancreatic cancer	5.69e-05	0.000576	CcSEcCtD
Haloperidol—CYP1A1—digestive system—pancreatic cancer	5.64e-05	0.019	CbGeAlD
Haloperidol—CYP3A5—digestive system—pancreatic cancer	5.52e-05	0.0186	CbGeAlD
Haloperidol—Feeling abnormal—Doxorubicin—pancreatic cancer	5.49e-05	0.000556	CcSEcCtD
Haloperidol—CYP2C9—digestive system—pancreatic cancer	5.43e-05	0.0183	CbGeAlD
Haloperidol—HRH1—digestive system—pancreatic cancer	5.35e-05	0.018	CbGeAlD
Haloperidol—Hypersensitivity—Epirubicin—pancreatic cancer	5.31e-05	0.000537	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—pancreatic cancer	5.29e-05	0.000536	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—pancreatic cancer	5.27e-05	0.000533	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—pancreatic cancer	5.09e-05	0.000516	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—pancreatic cancer	4.93e-05	0.000499	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—pancreatic cancer	4.91e-05	0.000497	CcSEcCtD
Haloperidol—ABCB1—islet of Langerhans—pancreatic cancer	4.88e-05	0.0165	CbGeAlD
Haloperidol—Dizziness—Epirubicin—pancreatic cancer	4.76e-05	0.000482	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—pancreatic cancer	4.71e-05	0.000477	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—pancreatic cancer	4.58e-05	0.000464	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—pancreatic cancer	4.56e-05	0.000462	CcSEcCtD
Haloperidol—Rash—Epirubicin—pancreatic cancer	4.54e-05	0.00046	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—pancreatic cancer	4.54e-05	0.000459	CcSEcCtD
Haloperidol—Headache—Epirubicin—pancreatic cancer	4.51e-05	0.000457	CcSEcCtD
Haloperidol—HTR2A—digestive system—pancreatic cancer	4.47e-05	0.0151	CbGeAlD
Haloperidol—Dizziness—Doxorubicin—pancreatic cancer	4.41e-05	0.000446	CcSEcCtD
Haloperidol—Nausea—Epirubicin—pancreatic cancer	4.28e-05	0.000433	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—pancreatic cancer	4.24e-05	0.000429	CcSEcCtD
Haloperidol—Rash—Doxorubicin—pancreatic cancer	4.2e-05	0.000425	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—pancreatic cancer	4.2e-05	0.000425	CcSEcCtD
Haloperidol—Headache—Doxorubicin—pancreatic cancer	4.17e-05	0.000423	CcSEcCtD
Haloperidol—CYP3A4—digestive system—pancreatic cancer	4.14e-05	0.014	CbGeAlD
Haloperidol—CYP2D6—digestive system—pancreatic cancer	4.07e-05	0.0137	CbGeAlD
Haloperidol—Nausea—Doxorubicin—pancreatic cancer	3.96e-05	0.000401	CcSEcCtD
Haloperidol—ABCB1—pancreas—pancreatic cancer	3.43e-05	0.0116	CbGeAlD
Haloperidol—ABCB1—digestive system—pancreatic cancer	2.93e-05	0.00988	CbGeAlD
Haloperidol—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	3.77e-06	5.38e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CASP3—pancreatic cancer	3.76e-06	5.36e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	3.75e-06	5.34e-05	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—AKT1—pancreatic cancer	3.75e-06	5.34e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	3.74e-06	5.33e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CASP3—pancreatic cancer	3.71e-06	5.29e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SRC—pancreatic cancer	3.7e-06	5.28e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—pancreatic cancer	3.68e-06	5.25e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—EGFR—pancreatic cancer	3.67e-06	5.24e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCND1—pancreatic cancer	3.66e-06	5.22e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	3.66e-06	5.21e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—STAT3—pancreatic cancer	3.65e-06	5.2e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SRC—pancreatic cancer	3.64e-06	5.19e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NRAS—pancreatic cancer	3.64e-06	5.18e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CTNNB1—pancreatic cancer	3.63e-06	5.17e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTEN—pancreatic cancer	3.62e-06	5.16e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCND1—pancreatic cancer	3.62e-06	5.15e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	3.62e-06	5.15e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PPARG—pancreatic cancer	3.61e-06	5.14e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	3.61e-06	5.14e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—pancreatic cancer	3.61e-06	5.14e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CTNNB1—pancreatic cancer	3.58e-06	5.1e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—STAT3—pancreatic cancer	3.57e-06	5.09e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NRAS—pancreatic cancer	3.56e-06	5.08e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—pancreatic cancer	3.56e-06	5.07e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—pancreatic cancer	3.55e-06	5.06e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	3.55e-06	5.05e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.54e-06	5.05e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTEN—pancreatic cancer	3.54e-06	5.04e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—STAT3—pancreatic cancer	3.51e-06	5.01e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.51e-06	5e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—pancreatic cancer	3.51e-06	5e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NRAS—pancreatic cancer	3.51e-06	4.99e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTEN—pancreatic cancer	3.49e-06	4.97e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	3.49e-06	4.97e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	3.48e-06	4.96e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	3.48e-06	4.96e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SRC—pancreatic cancer	3.48e-06	4.96e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	3.47e-06	4.95e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.46e-06	4.92e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—AKT1—pancreatic cancer	3.45e-06	4.92e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.45e-06	4.91e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	3.42e-06	4.87e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	3.41e-06	4.86e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—AKT1—pancreatic cancer	3.4e-06	4.85e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—APOE—pancreatic cancer	3.39e-06	4.83e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MYC—pancreatic cancer	3.39e-06	4.83e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	3.39e-06	4.83e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TGFB1—pancreatic cancer	3.38e-06	4.82e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	3.35e-06	4.78e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	3.35e-06	4.77e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—pancreatic cancer	3.32e-06	4.73e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EGFR—pancreatic cancer	3.31e-06	4.72e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	3.31e-06	4.72e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—APOE—pancreatic cancer	3.31e-06	4.71e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	3.29e-06	4.68e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SRC—pancreatic cancer	3.28e-06	4.67e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—pancreatic cancer	3.27e-06	4.65e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFB1—pancreatic cancer	3.26e-06	4.64e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TYMS—pancreatic cancer	3.25e-06	4.63e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	3.25e-06	4.62e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SRC—pancreatic cancer	3.24e-06	4.61e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CD44—pancreatic cancer	3.23e-06	4.61e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.21e-06	4.57e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	3.19e-06	4.55e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—pancreatic cancer	3.19e-06	4.55e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	3.19e-06	4.54e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—pancreatic cancer	3.16e-06	4.51e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NRAS—pancreatic cancer	3.16e-06	4.5e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—pancreatic cancer	3.15e-06	4.49e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	3.14e-06	4.47e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.13e-06	4.46e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	3.13e-06	4.46e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—pancreatic cancer	3.12e-06	4.45e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—APOE—pancreatic cancer	3.12e-06	4.44e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—pancreatic cancer	3.12e-06	4.44e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NRAS—pancreatic cancer	3.11e-06	4.44e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	3.11e-06	4.43e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GCG—pancreatic cancer	3.1e-06	4.42e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—APOE—pancreatic cancer	3.09e-06	4.4e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	3.09e-06	4.4e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	3.07e-06	4.37e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	3.06e-06	4.36e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	3.05e-06	4.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	3.04e-06	4.33e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—pancreatic cancer	3.04e-06	4.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	3.03e-06	4.32e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	3.03e-06	4.32e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—pancreatic cancer	3.02e-06	4.3e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—pancreatic cancer	3e-06	4.28e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CG—pancreatic cancer	2.99e-06	4.25e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	2.97e-06	4.23e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARG—pancreatic cancer	2.95e-06	4.21e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	2.95e-06	4.2e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—pancreatic cancer	2.94e-06	4.19e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	2.93e-06	4.18e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.93e-06	4.17e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	2.92e-06	4.16e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	2.92e-06	4.15e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—STK11—pancreatic cancer	2.91e-06	4.15e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	2.9e-06	4.14e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—pancreatic cancer	2.9e-06	4.13e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	2.9e-06	4.13e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	2.89e-06	4.12e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARG—pancreatic cancer	2.88e-06	4.11e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	2.88e-06	4.1e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	2.88e-06	4.1e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—pancreatic cancer	2.88e-06	4.1e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.87e-06	4.09e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	2.86e-06	4.08e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.84e-06	4.05e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—pancreatic cancer	2.84e-06	4.04e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—pancreatic cancer	2.84e-06	4.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.82e-06	4.02e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	2.82e-06	4.01e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	2.82e-06	4.01e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	2.81e-06	4.01e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	2.8e-06	3.99e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP3—pancreatic cancer	2.79e-06	3.98e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	2.79e-06	3.97e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—pancreatic cancer	2.78e-06	3.97e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	2.77e-06	3.95e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.77e-06	3.94e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.74e-06	3.9e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—pancreatic cancer	2.72e-06	3.88e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	2.72e-06	3.88e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—pancreatic cancer	2.72e-06	3.87e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—pancreatic cancer	2.72e-06	3.87e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.72e-06	3.87e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.7e-06	3.84e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARG—pancreatic cancer	2.69e-06	3.84e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	2.69e-06	3.83e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	2.69e-06	3.83e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.69e-06	3.83e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—pancreatic cancer	2.68e-06	3.82e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—pancreatic cancer	2.68e-06	3.82e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.67e-06	3.8e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	2.66e-06	3.79e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	2.65e-06	3.77e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	2.64e-06	3.77e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—APOE—pancreatic cancer	2.64e-06	3.76e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—pancreatic cancer	2.64e-06	3.76e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	2.63e-06	3.74e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CD—pancreatic cancer	2.62e-06	3.74e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—pancreatic cancer	2.62e-06	3.74e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—pancreatic cancer	2.62e-06	3.73e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	2.61e-06	3.71e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.61e-06	3.71e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—pancreatic cancer	2.56e-06	3.65e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	2.56e-06	3.65e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—pancreatic cancer	2.56e-06	3.65e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	2.56e-06	3.64e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	2.56e-06	3.64e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.51e-06	3.57e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.5e-06	3.56e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	2.5e-06	3.56e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—AKT1—pancreatic cancer	2.48e-06	3.54e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SRC—pancreatic cancer	2.48e-06	3.53e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—pancreatic cancer	2.48e-06	3.53e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	2.47e-06	3.52e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	2.46e-06	3.51e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	2.45e-06	3.49e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	2.45e-06	3.49e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SRC—pancreatic cancer	2.44e-06	3.47e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SRC—pancreatic cancer	2.43e-06	3.46e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—pancreatic cancer	2.41e-06	3.44e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	2.41e-06	3.44e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—pancreatic cancer	2.39e-06	3.4e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	2.38e-06	3.4e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRAS—pancreatic cancer	2.38e-06	3.39e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—pancreatic cancer	2.38e-06	3.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	2.37e-06	3.38e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	2.37e-06	3.37e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	2.35e-06	3.35e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	2.35e-06	3.35e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—pancreatic cancer	2.34e-06	3.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	2.34e-06	3.34e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	2.34e-06	3.34e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRAS—pancreatic cancer	2.34e-06	3.33e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—pancreatic cancer	2.32e-06	3.31e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—pancreatic cancer	2.31e-06	3.29e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	2.3e-06	3.28e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARG—pancreatic cancer	2.3e-06	3.28e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CB—pancreatic cancer	2.29e-06	3.26e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—pancreatic cancer	2.28e-06	3.25e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—pancreatic cancer	2.27e-06	3.23e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—AKT1—pancreatic cancer	2.26e-06	3.23e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—pancreatic cancer	2.22e-06	3.16e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	2.21e-06	3.15e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—pancreatic cancer	2.18e-06	3.11e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—pancreatic cancer	2.18e-06	3.1e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	2.18e-06	3.1e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	2.17e-06	3.1e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—pancreatic cancer	2.17e-06	3.09e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	2.16e-06	3.08e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.16e-06	3.07e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	2.14e-06	3.05e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.14e-06	3.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	2.14e-06	3.04e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—pancreatic cancer	2.13e-06	3.04e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—pancreatic cancer	2.12e-06	3.02e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.1e-06	2.99e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—AKT1—pancreatic cancer	2.09e-06	2.98e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—pancreatic cancer	2.05e-06	2.92e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—AKT1—pancreatic cancer	2.04e-06	2.9e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOE—pancreatic cancer	2.04e-06	2.9e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—pancreatic cancer	2.03e-06	2.89e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	2.02e-06	2.87e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—pancreatic cancer	2.01e-06	2.87e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—AKT1—pancreatic cancer	2.01e-06	2.87e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—pancreatic cancer	1.98e-06	2.82e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.88e-06	2.68e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.86e-06	2.65e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.85e-06	2.64e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	1.85e-06	2.64e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	1.85e-06	2.63e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—pancreatic cancer	1.85e-06	2.63e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.84e-06	2.62e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.83e-06	2.6e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.82e-06	2.6e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.81e-06	2.58e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—pancreatic cancer	1.79e-06	2.56e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—pancreatic cancer	1.79e-06	2.55e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.78e-06	2.53e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	1.75e-06	2.49e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.74e-06	2.48e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.72e-06	2.44e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—pancreatic cancer	1.71e-06	2.44e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.62e-06	2.3e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.58e-06	2.25e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.54e-06	2.19e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.51e-06	2.16e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—AKT1—pancreatic cancer	1.51e-06	2.15e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—AKT1—pancreatic cancer	1.51e-06	2.15e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	1.43e-06	2.04e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—AKT1—pancreatic cancer	1.43e-06	2.03e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.41e-06	2.01e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.4e-06	1.99e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—pancreatic cancer	1.39e-06	1.99e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.31e-06	1.87e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.3e-06	1.86e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.22e-06	1.74e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.17e-06	1.66e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—AKT1—pancreatic cancer	1.14e-06	1.62e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.11e-06	1.59e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.07e-06	1.53e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.06e-06	1.52e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—AKT1—pancreatic cancer	9.1e-07	1.3e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	8.59e-07	1.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—AKT1—pancreatic cancer	7.02e-07	1e-05	CbGpPWpGaD
